Skip to main content

Pharma News

Crack GPAT — Prepare for GPAT Online 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan

    Takeda announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid® Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older. Novavax licensed and transferred its manufacturing technologies to enable Takeda to develop and manufacture the vaccine at its facility in Hikari. Takeda will begin distribution of Nuvaxovid doses purchased by the Government of Japan as soon as possible.

  • SII pneumococcal vaccine gets exemption from price control

    Serum institute of India, SII, gets exemption for Pneumococcal Polysaccharide Conjugate Vaccine from price control by National Pharmaceutical Pricing Authority  for five years.

  • From cell fat to cell fate

    How does a cell “decide” what type of cell to become? The question of “cell fate” has been explored for decades now, especially in the context of stem cell biology, but there are still gaps in our understanding. For example, any multicellular organism is made up of different cell types that play specific roles, while they all work together to sustain the organism as a whole.

  • Novel therapeutic agents may reduce the oncogenesis of metastatic prostate cancer

    Researchers have found that treating prostate cancer cells with novel cyclin-dependent kinase 19 (CDK19) and homologous cyclin-dependent kinase 8 (CDK8) inhibitors reduces their potential to migrate into and invade surrounding structures. These molecules may be used as single or combination therapy for patients with advanced disease to prevent and treat metastatic spread. The results appear in The American Journal of Pathology, published by Elsevier.

  • Tumors partially destroyed with sound don’t come back

    Noninvasive sound technology developed at the University of Michigan breaks down liver tumors in rats, kills cancer cells and spurs the immune system to prevent further spread an advance that could lead to improved cancer outcomes in humans.  By destroying only 50% to 75% of liver tumor volume, the rats’ immune systems were able to clear away the rest, with no evidence of recurrence or metastases in more than 80% of animals.

  • In-Cosmetics Global 2022 Exhibition & Conference

    In-Cosmetics Global 2022 Exhibition & Conference was held in Paris, France from 5th to 7th April 2022. It was focused on Innovation, be it innovation in Functional ingredients, Active ingredients, Green ingredients, Sensorial ingredients and it recognized the very best of the industry’s innovation by awarding them.

  • Newly identified cell type could be the key to restoring damaged salivary glands

    Scientists at Scripps Research and the National Institute of Dental and Craniofacial Research have discovered a special type of cell that resides in salivary glands and is likely crucial for oral health.

  • Basilea reports preclinical data on oncology drug candidates BAL0891

    Basilea Pharmaceutica Ltd a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, reported today that promising preclinical data on the anti-cancer activity of its three oncology drug candidates, BAL0891, derazantinib and lisavanbulin, have been presented at the Annual Meeting of the American Association for Cancer Research (AACR) that took place April 8-13, 2022, in New Orleans, USA.

  • Researchers Identify a New Treatment for Metabolic Syndrome

    Metabolic syndrome increases a person’s risk for diabetes, heart disease, and stroke, and includes conditions such as obesity, high blood pressure and high blood sugar. In a recent mouse-model study, published in Cell Metabolism, researchers at University Hospitals (UH), Harrington Discovery Institute at UH, and Case Western Reserve University have furthered their progress to develop a drug to treat metabolic syndrome by identifying a receptor that controls appetite and body weight.

  • SARS-CoV-2 : Neutralization of BA.1 and BA.2 by Therapeutic Monoclonal Antibodies

    The SARS-CoV-2 Omicron BA.1 sublineage has been supplanted in many countries by the BA.2 sublineage. Although Omicron is responsible for less severe forms in the general population, immunocompromised people are still at higher risk of developing severe forms of COVID-19. Several monoclonal antibodies are currently available in clinical practice as a preventive treatment for these patients.

Subscribe to Pharma News